Splenic venous hypertension (SVH), also known as left-sided portal hypertension, is a rare condition characterized by upper gastrointestinal (GI) bleeding in the absence of liver disease. This condition arises due to increased ...
10 hours ago
0
0
A treatment for metastatic cancer—researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), the University of Innsbruck, the Massachusetts Institute of Technology (MIT) and Universität Würzburg have now ...
15 hours ago
0
43
Scientists at Nottingham Trent University, the University of Nottingham, Stanford University and the University of California and Cedars-Sinai Medical Center, Los Angeles, have found that the molecule "HNF4A" suppresses pancreatic ...
Jul 15, 2024
0
41
Obesity increases the risk of developing a number of cancers, so it stands to reason that drugs that reduce body weight should also reduce the risk of developing these cancers.
Jul 13, 2024
0
1
Mutations in the KRAS gene are the primary driver of pancreatic cancer. A new class of drugs known as KRAS inhibitors is showing initial promise in clinical trials, but many tumors quickly develop resistance to the treatment.
Jul 11, 2024
0
19
Patients with advanced cases of pancreatic cancer have a poor survival rate, and in the early stages the cancer does not usually produce any noticeable symptoms.
Jul 8, 2024
0
1
A molecule called nidogen-2 may be a key driver of pancreatic cancer progression and metastasis, offering a promising new treatment approach for this aggressive cancer, according to a Garvan Institute study.
Jul 8, 2024
0
51
A team at the Institute of Biochemistry at Kiel University has found a way to inhibit the function of the tumor-causing protein MYC. This can be used to develop new drugs.
Jul 4, 2024
0
42
Pancreatic cancer is a particularly aggressive and difficult-to-treat cancer, in part because it is often resistant to chemotherapy. Now, researchers at Stanford have revealed that this resistance is related to both the physical ...
Jul 4, 2024
0
44
Researchers at Weill Cornell Medicine with an international team have used liver biopsies to identify cellular and molecular markers that can potentially be used to predict whether and when pancreatic cancer will spread to ...
Jun 28, 2024
0
28
Pancreatic cancer refers to a malignant neoplasm originating from transformed cells arising in tissues forming the pancreas. The most common type of pancreatic cancer, accounting for 95% of these tumors, is adenocarcinoma (tumors exhibiting glandular architecture on light microscopy) arising within the exocrine component of the pancreas. A minority arise from islet cells, and are classified as neuroendocrine tumors. The symptoms that lead to diagnosis depend on the location, the size, and the tissue type of the tumor. They may include abdominal pain and jaundice (if the tumor compresses the bile duct).
Pancreatic cancer is the fourth most common cause of cancer death across the globe. Pancreatic cancer often has a poor prognosis: for all stages combined, the 1- and 5-year relative survival rates are 25% and 6%, respectively; for local disease the 5-year survival is approximately 20% while the median survival for locally advanced and for metastatic disease, which collectively represent over 80% of individuals, is about 10 and 6 months respectively.
This text uses material from Wikipedia licensed under CC BY-SA
